Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Summary

GlobalData’s new report, “Drug Eluting Stents - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global drug eluting stents market. The report provides market landscape, competitive landscape and market trends information on the drug eluting stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.
- Qualitative analysis of key market trends, market drivers, and restraints for drug eluting stents market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include Abbott Laboratories, Boston Scientific, Cordis Corporation and Medtronic.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the drug eluting stents market globally.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the drug eluting stents market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global drug eluting stents market and the factors shaping it.

Table Of Contents

Table of Contents

1 Table of contents
1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 GlobalData Report Guidance 10
3 Disease Overview - Coronary Heart Disease (CHD) 11
3.1 Etiology 11
3.2 Risk Factors 11
3.3 Signs and Symptoms 11
3.4 Diagnosis 12
3.4.1 Electrocardiogram (ECG) 12
3.4.2 Echocardiogram 12
3.4.3 Blood Tests 12
3.4.4 Coronary Angiography 12
3.4.5 Radionuclide tests 12
3.4.6 Magnetic Resonance Imaging (MRI) 12
3.5 Epidemiology 12
3.5.1 Prevalence of CHD in the US 12
3.5.2 Prevalence of CHD in the UK 12
4 Device Overview - Drug Eluting Stents (DES) 13
4.1 Drug Eluting Stents: Risk Factors 14
4.1.1 Stent Thrombosis (ST) 14
5 Drug Eluting Stents - Market Characterization 15
5.1 Drug Eluting Stents Market, Global, Revenue ($m), Historic, 2003-2010 15
5.2 Drug Eluting Stents Market, Global, Revenue ($m), Forecast, 2010-2017 16
5.3 Drug Eluting Stents Market, Global, Volume (‘000), Historic, 2003-2010 17
5.4 Drug Eluting Stents Market, Global, Volume (‘000), Forecast, 2010-2017 18
5.5 Drug Eluting Stents, Market Dynamics 19
5.5.1 Market Drivers 20
5.5.2 Market Restraints 34
6 Drug Eluting Stents (DES) Market, Analysis by Country, Revenue ($m), 2003-2017 36
6.1 Drug Eluting Stents Market, the US, Revenue ($bn), Historic, 2003-2010 36
6.2 Drug Eluting Stents Market, the US, Volume (million), Historic, 2003-2010 37
6.3 Drug Eluting Stents Market, the US, Revenue ($bn), Forecast, 2010-2017 38
6.4 Drug Eluting Stents Market, the US, Volume (million), Forecast, 2010-2017 39
6.5 Drug Eluting Stents Market, Canada, Revenue ($m), Historic, 2003-2010 40
6.6 Drug Eluting Stents Market, Canada, Volume (‘000), Historic, 2003-2010 41
6.7 Drug Eluting Stents Market, Canada, Revenue ($m), Forecast, 2010-2017 42
6.8 Drug Eluting Stents Market, Canada, Volume (‘000), Forecast, 2010-2017 43
6.9 Drug Eluting Stents Market, the UK, Revenue ($m), Historic, 2003-2010 44
6.10 Drug Eluting Stents Market, the UK, Volume (‘000), Historic, 2003-2010 45
6.11 Drug Eluting Stents Market, the UK, Revenue ($m), Forecast, 2010-2017 46
6.12 Drug Eluting Stents Market, the UK, Volume (‘000), Forecast, 2010-2017 47
6.13 Drug Eluting Stents Market, Germany, Revenue ($m), Historic, 2003-2010 48
6.14 Drug Eluting Stents Market, Germany, Volume (‘000), Historic, 2003-2010 49
6.15 Drug Eluting Stents Market, Germany, Revenue ($m), Forecast, 2010-2017 50
6.16 Drug Eluting Stents Market, Germany, Volume (‘000), Forecast, 2010-2017 51
6.17 Drug Eluting Stents Market, France, Revenue ($m), Historic, 2003-2010 52
6.18 Drug Eluting Stents Market, France, Volume (‘000), Historic, 2003-2010 53
6.19 Drug Eluting Stents Market, France, Revenue ($m), Forecast, 2010-2017 54
6.20 Drug Eluting Stents Market, France, Volume (‘000), Forecast, 2010-2017 55
6.21 Drug Eluting Stents Market, Italy, Revenue ($m), Historic, 2003-2010 56
6.22 Drug Eluting Stents Market, Italy, Volume (‘000), Historic, 2003-2010 57
6.23 Drug Eluting Stents Market, Italy, Revenue ($m), Forecast, 2010-2017 58
6.24 Drug Eluting Stents Market, Italy, Volume (‘000), Forecast, 2010-2017 59
6.25 Drug Eluting Stents Market, Spain, Revenue ($m), Historic, 2003-2010 60
6.26 Drug Eluting Stents Market, Spain, Volume (‘000), Historic, 2003-2010 61
6.27 Drug Eluting Stents Market, Spain, Revenue ($m), Forecast, 2010-2017 62
6.28 Drug Eluting Stents Market, Spain, Volume (‘000), Forecast, 2010-2017 63
6.29 Drug Eluting Stents Market, Japan, Revenue ($m), Historic, 2003—2010 64
6.30 Drug Eluting Stents Market, Japan, Volume (‘000), Historic, 2003—2010 65
6.31 Drug Eluting Stents Market, Japan, Revenue ($m), Forecast, 2010—2017 66
6.32 Drug Eluting Stents Market, Japan, Volume (‘000), Forecast, 2010—2017 67
6.33 Drug Eluting Stents Market, China, Revenue ($m), Historic, 2003—2010 68
6.34 Drug Eluting Stents Market, China, Volume (‘000), Historic, 2003—2010 69
6.35 Drug Eluting Stents Market, China, Revenue ($m), Forecast, 2010—2017 70
6.36 Drug Eluting Stents Market, China, Volume (‘000), Forecast, 2010—2017 71
6.37 Drug Eluting Stents Market, India, Revenue ($m), Historic, 2003—2010 72
6.38 Drug Eluting Stents Market, India, Volume (‘000), Historic, 2003—2010 73
6.39 Drug Eluting Stents Market, India, Revenue ($m), Forecast, 2010—2017 74
6.40 Drug Eluting Stents Market, India, Volume (‘000), Forecast, 2010-2017 75
6.41 Drug Eluting Stents Market, Australia, Revenue ($m), Historic, 2003-2010 76
6.42 Drug Eluting Stents Market, Australia, Volume (‘000), Historic, 2003-2010 77
6.43 Drug Eluting Stents Market, Australia, Revenue ($m), Forecast, 2010-2017 78
6.44 Drug Eluting Stents Market, Australia, Volume (‘000), Forecast, 2010-2017 79
6.45 Drug Eluting Stents Market, Brazil, Revenue ($m), Historic, 2003-2010 80
6.46 Drug Eluting Stents Market, Brazil, Volume (‘000), Historic, 2003-2010 81
6.47 Drug Eluting Stents Market, Brazil, Revenue ($m), Forecast, 2010-2017 82
6.48 Drug Eluting Stents Market, Brazil, Volume (‘000), Forecast, 2010-2017 83
7 Drug Eluting Stents Market - Strategic Competitive Assessment 84
7.1 Drug Eluting Stents Market: Key Player Profiles 85
7.1.1 Boston Scientific 85
7.1.2 Abbott Laboratories 90
7.1.3 Medtronic Inc. 93
7.1.4 Cordis Corporation 96
8 Drug Eluting Stents - Key Marketed Products 100
8.1 TAXUS Liberte Paclitaxel-Eluting Coronary Stent System 100
8.1.1 Product Description 100
8.1.2 Features and Benefits 100
8.2 PROMUS Everolimus-Eluting Coronary Stent System 101
8.2.1 Product Description 101
8.2.2 Features and Benefits 101
8.3 XIENCE V Everolimus-Eluting Coronary Stent System 101
8.3.1 Product Description 101
8.3.2 Features and Benefits 101
8.4 CYPHER Sirolimus-Eluting Coronary Stent 101
8.4.1 Product Description 101
8.4.2 Features and Benefits 101
8.5 Endeavor Zotarolimus-Eluting Stent System 101
8.5.1 Product Description 101
8.5.2 Features and Benefits 101
9 Drug Eluting Stents Market - Strategic Pipeline Assessment 102
9.1 Bioabsorbable Drug-eluting Stents 102
9.1.1 Key Pipeline Products 102
9.2 Drug Eluting Stents, Pipeline Assessment, by Development Stage 116
9.3 Profiles of Promising Products under Clinical Development 116
9.3.1 TAXUS Element (ION) Paclitaxel-Eluting Coronary Stent System 116
9.3.2 XIENCE PRIME Everolimus-Eluting Coronary Stent System 122
9.3.3 JACTAX Drug-eluting Stent 129
9.3.4 PROMUS Element Everolimus-Eluting Coronary Stent 136
9.3.5 Synergy Coronary Stent 146
9.3.6 AVJ-09-385 148
9.3.7 ZoMaxx Drug Eluting Coronary Stent System 152
9.3.8 NEVO Sirolimus-Eluting Coronary Stent 153
9.3.9 Endeavor Resolute 162
10 Drug Eluting Stents Market - Deals Landscape 176
10.1 Drug Eluting Stents Marke - Deals Overview 176
10.2 Key Deals (2009-2010) 176
10.2.1 Biosensors International Group Acquired Assets from Devax 176
10.2.2 Xenogenics Acquired Assets of Ideal BioStent 177
10.2.3 Biosensors International acquires CardioMind 177
10.2.4 Boston Scientific acquires Labcoat 177
10.2.5 Svelte Medical Systems enters into Licensing Agreement with Cordis 178
11 Appendix 179
11.1 Definitions 179
11.1.1 Drug Eluting Stent (DES) 179
11.2 Abbreviations (in alphabetical order) 180
11.3 Research Methodology 182
11.3.1 Secondary Research 182
11.3.2 Primary Research 183
11.3.3 Models 183
11.3.4 Forecasts 183
11.3.5 Expert Panel 184
11.4 GlobalData Consulting 184
11.5 Contact Us 184
11.6 Disclaimer 184
11.7 Sources 184

List of Tables

1.1 List of Tables
Table 1: Drug Eluting Stents, Classified by Drug Used, 2010 13
Table 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010 15
Table 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017 16
Table 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010 17
Table 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017 18
Table 6: Coronary Heart Disease, the US, Prevalence (%), 2010-2030 20
Table 7: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008 21
Table 8: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008 22
Table 9: Population Aged 65 and Above, Global, Population (million), 2004-2010 23
Table 10: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050 24
Table 11: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006 25
Table 12: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050 26
Table 13: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008 27
Table 14: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008 28
Table 15: Tobacco Consumption, Global, Population (billion), 2000—2050 29
Table 16: Diabetes Prevalence, by Country, Prevalence (%), Latest Data Available 30
Table 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010 31
Table 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010 32
Table 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010 33
Table 20: Drug Eluting Stents Market, by Country, Average Selling Price ($), 2003-2010 34
Table 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010 36
Table 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010 37
Table 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017 38
Table 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017 39
Table 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010 40
Table 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010 41
Table 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017 42
Table 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017 43
Table 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010 44
Table 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010 45
Table 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017 46
Table 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017 47
Table 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010 48
Table 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010 49
Table 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017 50
Table 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017 51
Table 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010 52
Table 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010 53
Table 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017 54
Table 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017 55
Table 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010 56
Table 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010 57
Table 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017 58
Table 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017 59
Table 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010 60
Table 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010 61
Table 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017 62
Table 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017 63
Table 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003—2010 64
Table 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003—2010 65
Table 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010—2017 66
Table 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010—2017 67
Table 53: Drug Eluting Stents Market, China, Revenue ($m), 2003—2010 68
Table 54: Drug Eluting Stents Market, China, Volume (‘000), 2003—2010 69
Table 55: Drug Eluting Stents Market, China, Revenue ($m), 2010—2017 70
Table 56: Drug Eluting Stents Market, China, Volume (‘000), 2010—2017 71
Table 57: Drug Eluting Stents Market, India, Revenue ($m), 2003—2010 72
Table 58: Drug Eluting Stents Market, India, Volume (‘000), 2003—2010 73
Table 59: Drug Eluting Stents Market, India, Revenue ($m), 2010—2017 74
Table 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017 75
Table 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010 76
Table 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010 77
Table 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017 78
Table 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017 79
Table 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010 80
Table 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010 81
Table 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017 82
Table 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017 83
Table 69: Drug Eluting Stents Market, Global, Company Share ($m), 2010 84
Table 70: Boston Scientific Marketed Products, 2011 86
Table 71: Boston Scientific Pipeline Products, 2011 87
Table 72: Abbott Laboratories Marketed Products, 2011 90
Table 73: Abbott Laboratories Pipeline Products, 2011 91
Table 74: Medtronic Inc. Marketed Products, 2011 93
Table 75: Medtronic Inc. Pipeline Products, 2011 94
Table 76: Cordis Corporation Marketed Products, 2011 96
Table 77: Cordis Corporation Pipeline Products, 2011 97
Table 78: Absorb Product Status 102
Table 79: Absorb Clinical Trial 1 103
Table 80: Absorb Clinical Trial 2 104
Table 81: Absorb Clinical Trial 3 106
Table 82: Bioresorbable Stent Product Status 107
Table 83: Biosorb Product Status 107
Table 84: Drug Eluting Absorbable Metal Scaffold Product Status 108
Table 85: Drug Eluting Absorbable Metal Scaffold Clinical Trials 108
Table 86: Fully Biodegradable Stent Product Status 109
Table 87: IDEAL Stent Product Status 110
Table 88: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Product Status 110
Table 89: Myolimus-Eluting Coronary Stent - Bioabsorbable Polymer Clinical Trials 111
Table 90: Peptide-Eluting Coronary Stent Product Status 112
Table 91: RESORB Product Status 112
Table 92: ReZolve Bioresorbable Coronary Stent Product Status 112
Table 93: ReZolve Bioresorbable Coronary Stent Clinical Trials 113
Table 94: TephaFLEX Absorbable Stent Product Status 114
Table 95: Whisper Coronary Stent System Product Status 114
Table 96: Whisper Coronary Stent System Clinical Trials 115
Table 97: Product Status 116
Table 98: TAXUS Element Clinical Trial 1 117
Table 99: TAXUS Element Clinical Trial 2 119
Table 100: TAXUS Element Clinical Trial 3 121
Table 101: Product Status 122
Table 102: XIENCE PRIME Clinical Trial 1 123
Table 103: DARE Trial 124
Table 104: XIENCE PRIME Clinical Trial 3 125
Table 105: XIENCE PRIME Clinical Trial 4 127
Table 106: XIENCE PRIME Clinical Trial 5 128
Table 107: Product Status 129
Table 108: JACTAX Clinical Trial 1 130
Table 109: JACTAX Clinical Trial 2 132
Table 110: JACTAX Clinical Trial 3 134
Table 111: Product Status 136
Table 112: PROMUS Clinical Trial 1 136
Table 113: PROMUS Clinical Trial 2 138
Table 114: PROMUS Clinical Trial 3 140
Table 115: PROMUS Clinical Trial 4 (EVOLVE) 142
Table 116: PROMUS Clinical Trail 5 144
Table 117: PROMUS Clinical Trial 6 145
Table 118: Product Status 146
Table 119: Synergy Clinical Trial (EVOLVE) 147
Table 120: Product Status 148
Table 121: AVJ-09-385 Clinical Trial 148
Table 122: Product Status 152
Table 123: ZoMaxx Clinical Trial 152
Table 124: Product Status 153
Table 125: NEVO Clinical Trial 1 154
Table 126: NEVO Clinical Trial 2 156
Table 127: NEVO Clinical Trial 3 157
Table 128: NEVO Clinical Trial 4 158
Table 129: NEVO Clinical Trial 5 159
Table 130: NEVO Clinical Trial 6 161
Table 131: Product Status 162
Table 132: Endeavor Resolute Clinical Trial 1 163
Table 133: Endeavor Resolute Clinical Trial 2 165
Table 134: Endeavor Resolute Clinical Trial 3 166
Table 135: Endeavor Resolute Clinical Trial 4 167
Table 136: Endeavor Resolute Clinical Trial 5 168
Table 137: Endeavor Resolute Clinical Trial 6 169
Table 138: Endeavor Resolute Clinical Trial 7 170
Table 139: Endeavor Resolute Clinical Trial 8 171
Table 140: Endeavor Resolute Clinical Trial 9 173
Table 141: Endeavor Resolute Clinical Trial 10 174

List of Figures

1.2 List of Figures
Figure 1: Coronary Heart Disease, Signs and Symptoms 11
Figure 2: Drug Eluting Stents Market, Global, Revenue ($m), 2003-2010 15
Figure 3: Drug Eluting Stents Market, Global, Revenue ($m), 2010-2017 16
Figure 4: Drug Eluting Stents Market, Global, Volume (‘000), 2003-2010 17
Figure 5: Drug Eluting Stents Market, Global, Volume (‘000), 2010-2017 18
Figure 6: Drug Eluting Stents, Global, Market Dynamics 19
Figure 7: Coronary Heart Disease, the US, Prevalence (%), 2010-2030 20
Figure 8: Coronary Heart Disease in Men by Age, the UK, Prevalence (%), 2000-2008 21
Figure 9: Coronary Heart Disease in Women by Age, the UK, Prevalence (%), 2000-2008 22
Figure 10: Population Aged 65 and Above, Global, Population (million), 2004-2010 23
Figure 11: Population Aged 60 and Above, the US, Population (million) and Population Aged 60 and Above as a Percentage (%) of Adult Population, 2000-2050 24
Figure 12: Prevalence of Coronary Heart Disease in Population Aged between 60-79 and Population Aged 80 and Above, the US, Prevalence (%), 2006 25
Figure 13: Population Aged 65 and above, the UK, Population (million) and Population Aged 65 and Above as a Percentage (%) of Adult Population, 2000-2050 26
Figure 14: Coronary Heart Disease in Men Aged 65 and Above, the UK, Prevalence (%), 2000-2008 27
Figure 15: Coronary Heart Disease in Women Aged 65 and Above, the UK, Prevalence (%), 2000-2008 28
Figure 16: Tobacco Consumption, Global, Population (billion), 2000—2050 29
Figure 17: Percutaneous Coronary Intervention Procedure (million), Global, 2003-2010 31
Figure 18: Percutaneous Coronary Intervention Procedure (million), the US, 2003-2010 32
Figure 19: Percutaneous Coronary Intervention Procedure (‘000), Europe, 2003-2010 33
Figure 20: Drug Eluting Stents, the US and the UK, Average Selling Price ($), 2003-2010 34
Figure 21: Drug Eluting Stents Market, the US, Revenue ($bn), 2003-2010 36
Figure 22: Drug Eluting Stents Market, the US, Volume (million), 2003-2010 37
Figure 23: Drug Eluting Stents Market, the US, Revenue ($bn), 2010-2017 38
Figure 24: Drug Eluting Stents Market, the US, Volume (million), 2010-2017 39
Figure 25: Drug Eluting Stents Market, Canada, Revenue ($m), 2003-2010 40
Figure 26: Drug Eluting Stents Market, Canada, Volume (‘000), 2003-2010 41
Figure 27: Drug Eluting Stents Market, Canada, Revenue ($m), 2010-2017 42
Figure 28: Drug Eluting Stents Market, Canada, Volume (‘000), 2010-2017 43
Figure 29: Drug Eluting Stents Market, the UK, Revenue ($m), 2003-2010 44
Figure 30: Drug Eluting Stents Market, the UK, Volume (‘000), 2003-2010 45
Figure 31: Drug Eluting Stents Market, the UK, Revenue ($m), 2010-2017 46
Figure 32: Drug Eluting Stents Market, the UK, Volume (‘000), 2010-2017 47
Figure 33: Drug Eluting Stents Market, Germany, Revenue ($m), 2003-2010 48
Figure 34: Drug Eluting Stents Market, Germany, Volume (‘000), 2003-2010 49
Figure 35: Drug Eluting Stents Market, Germany, Revenue ($m), 2010-2017 50
Figure 36: Drug Eluting Stents Market, Germany, Volume (‘000), 2010-2017 51
Figure 37: Drug Eluting Stents Market, France, Revenue ($m), 2003-2010 52
Figure 38: Drug Eluting Stents Market, France, Volume (‘000), 2003-2010 53
Figure 39: Drug Eluting Stents Market, France, Revenue ($m), 2010-2017 54
Figure 40: Drug Eluting Stents Market, France, Volume (‘000), 2010-2017 55
Figure 41: Drug Eluting Stents Market, Italy, Revenue ($m), 2003-2010 56
Figure 42: Drug Eluting Stents Market, Italy, Volume (‘000), 2003-2010 57
Figure 43: Drug Eluting Stents Market, Italy, Revenue ($m), 2010-2017 58
Figure 44: Drug Eluting Stents Market, Italy, Volume (‘000), 2010-2017 59
Figure 45: Drug Eluting Stents Market, Spain, Revenue ($m), 2003-2010 60
Figure 46: Drug Eluting Stents Market, Spain, Volume (‘000), 2003-2010 61
Figure 47: Drug Eluting Stents Market, Spain, Revenue ($m), 2010-2017 62
Figure 48: Drug Eluting Stents Market, Spain, Volume (‘000), 2010-2017 63
Figure 49: Drug Eluting Stents Market, Japan, Revenue ($m), 2003—2010 64
Figure 50: Drug Eluting Stents Market, Japan, Volume (‘000), 2003—2010 65
Figure 51: Drug Eluting Stents Market, Japan, Revenue ($m), 2010—2017 66
Figure 52: Drug Eluting Stents Market, Japan, Volume (‘000), 2010—2017 67
Figure 53: Drug Eluting Stents Market, China, Revenue ($m), 2003—2010 68
Figure 54: Drug Eluting Stents Market, China, Volume (‘000), 2003—2010 69
Figure 55: Drug Eluting Stents Market, China, Revenue ($m), 2010—2017 70
Figure 56: Drug Eluting Stents Market, China, Volume (‘000), 2010—2017 71
Figure 57: Drug Eluting Stents Market, India, Revenue ($m), 2003—2010 72
Figure 58: Drug Eluting Stents Market, India, Volume (‘000), 2003—2010 73
Figure 59: Drug Eluting Stents Market, India, Revenue ($m), 2010—2017 74
Figure 60: Drug Eluting Stents Market, India, Volume (‘000), 2010-2017 75
Figure 61: Drug Eluting Stents Market, Australia, Revenue ($m), 2003-2010 76
Figure 62: Drug Eluting Stents Market, Australia, Volume (‘000), 2003-2010 77
Figure 63: Drug Eluting Stents Market, Australia, Revenue ($m), 2010-2017 78
Figure 64: Drug Eluting Stents Market, Australia, Volume (‘000), 2010-2017 79
Figure 65: Drug Eluting Stents Market, Brazil, Revenue ($m), 2003-2010 80
Figure 66: Drug Eluting Stents Market, Brazil, Volume (‘000), 2003-2010 81
Figure 67: Drug Eluting Stents Market, Brazil, Revenue ($m), 2010-2017 82
Figure 68: Drug Eluting Stents Market, Brazil, Volume (‘000), 2010-2017 83
Figure 69: Drug Eluting Stents Market, Global, Company Share (%), 2010 84
Figure 70: Boston Scientific Corporation, SWOT Analysis 88
Figure 71: Abbott Laboratories, SWOT Analysis 92
Figure 72: Medtronic Inc., SWOT Analysis 94
Figure 73: Cordis Corporation, SWOT Analysis 98
Figure 74: Drug Eluting Stents Market, Key Marketed Products 100
Figure 75: Pipeline Products, by Development Stage, 2011 116
Figure 76: Drug Eluting Stents, Deals Landscape, 2009-2010 176

Companies Mentioned

Boston Scientific
Abbott Laboratories
Medtronic Inc.
Cordis Corporation

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Prosthetic Heart Valves Industry

Global Prosthetic Heart Valves Industry

  • $ 4 950
  • Industry report
  • June 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Prosthetic Heart Valves in US$ Million by the following Product Segments: Mechanical valves, and Biological/Tissue valves. The report provides separate comprehensive ...

Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019

Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

This report studies the current as well as future prospects of the coronary stents market globally. The market for coronary stents is categorized into three major segments, namely, bare metal stents (BMS), ...

Cardiovascular Monitoring & Diagnostic Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop Recorders, ECG Management Systems) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013

Cardiovascular Monitoring & Diagnostic Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop Recorders, ECG Management Systems) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

This report covers the market analysis for various devices used for diagnosing and monitoring of cardiovascular diseases. The stakeholders for this study include the present manufacturers and providers ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.